Title: Research Towards a LongerActing FactorVIII
1 Research Towards aLonger-Acting Factor VIII
CURE
Convenience
t1/2 Improvement
Optimal Therapy
Bruce M. Ewenstein, MD, PhD Global Medical
Director Baxter BioScience
Pathogen Safety
- Plasma-Albumin Free Method
2Molecular Mechanism of FVIII Clearance
Ananyeva et al., 2001 Saenko EL and Ananyeva NM,
2006
3Potential Targets for FVIIIHalf-Life Extension
- Indirect modifications
- Interference with FVIII receptor mediated
clearance - Formulations with improved stability
- PEGylated liposomes
- Modification of VWF as the FVIII carrier protein
- VWF mutant
- Biochemical modificationof VWF
- Direct modifications
- FVIII Mutants
- Resistant to degradation
- Resistant to inactivation
- Resistant to clearance
- Biochemical modification of FVIII
- PEGylation
- Modifications of glycosylation
4Concepts for a Next-Generation Hemophilia A
Therapy With Improved Pharmacokinetics
- Baxter is developing 4 approaches for half-life
extension of Factor VIII (FVIII), pursuing both
direct and indirect modification
TARGET
APPROACH
rVWF recombinant von Willebrands factor.
5PEGylationDerivatization of Proteins With
Synthetic Polyethylene Glycol
- Knowns
- Enhanced solubility
- Decreased proteolysis
- Altered distribution and absorption
- Enhanced storage stability
- Increased half-life
- Unknowns
- Clearance mechanism of large PEG-protein
conjugates - Effects of long-term exposure
- Impact on immunogenicity
mPEG2-SBA (Succinimidyl butyrate)
6PEGylated rFVIII Showed ImprovedPK Parameters
Compared With rFVIII Half-life Increased 2-fold
PEGylated rFVIII In Vivo Evaluation in
FVIII-Deficient Mice
Application of PEG-rFVIII or rFVIII (200 IU
FVIII/kg)
10.00
PEG-rFVIII (200 U/kg)
rFVIII (200 U/kg)
AUC (mUhr/mL)/(mU/kg)
1.00
FVIII (IU/mL) SD
126
65
0.10
n5
0.01
0
10
20
30
Hours Post-infusion
Calculation with MS Excel. AUC area under the
curve.
7VWF as a Target for the Prolongation of the
Half-Life of FVIII
- The survival of FVIII in the circulation is
dependent on its chaperone VWF - VWF rapidly forms a tight complex with FVIII with
high affinity - FVIII-VWF complex formation may prevent FVIII
from interacting with lower affinity binding
partners, such as FIXa, phospholipids and LRP - FVIII bound to VWF is protected from enzymatic
(in)activation - Correlation between pre-infusion from VWF levels
andhalf-life of FVIII in severe hemophilia A1,2
1. Fijnvandraat et al., Br J Haematol.
199591474-6. 2. Vloet et al., Thromb
Haemost. 200078365-9.
8rVWF Largest Protein Ever Successfully PEGylated
VWF multimer
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
PEGylation
PEGylated VWF multimer
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
Immunoblot withanti-PEG pAb
Coomassie staining
kDa
- SDS-PAGE (reduced)
- Increase in MW
- after PEGylation
- Multimer distribution
- (2.5 agarose)
- Broadening of all multimer bands in
PEGylated rVWF
MW marker
MW marker
PEG-rVWF 5K
Native rVWF
Native rVWF
PEG-rVWF 5K
PEG-rVWF 20K
PEG-rVWF 20K
9Substantial Half-life Increase for rVWF After
PEGylation
PEG-rVWF in FVIII-deficient KO mice
10PEG-rVWF Demonstrated Substantial Half-life
Increase of FVIII
PEG-rVWF in FVIII-Deficient KO Mice
Dose (200/300 U/kg)
PEG-rVWF / rFVIII
100.0
rVWF / rFVIII
AUC 102
10.0
FVIII ( from Umax)
1.0
AUC 40
n5
0.1
0
5
10
15
20
25
30
35
Hours Post-infusion
(mUh/mL)/(mU/kg).
11Polysialic Acid (PSA) Technology as an
Alternative to PEGylation
- Features of PSA
- ?-2,8-linked polysialic acid
- Negatively chargedhydrophilic polymer
- Natural constituent of human tissue
- Non-immunogenic
- Biodegradable (to sialic acid)
- Chemical derivatization of proteins with PSA
- Preferred process conjugation with Lys residues
by reductive amination
12Polysialylation Prolonged VWFHalf-life and
Sustained the Secondary Rise of FVIII
rVWF-polysialic acid conjugate PK in VWD mice
PSA-rVWF (80 IU VWFAg/kg)
rVWF (70 IU VWFAg/kg)
rVWF-PSA
rVWF-PSA
10.0
0.6
rVWF
rVWF
AUC 66
1.0
0.4
AUC 68
VWFAg (U/mL)
FVIII (U/mL)
0.2
0.1
AUC 47
AUC 50
FVIII base level in VWD mice
0.0
0.0
0
5
10
15
20
25
0
5
10
15
20
25
Hours Post-infusion
Hours Post-infusion
(mUh/mL)/(mU/kg). VWD von Willebrand disease.
13Factor VIII Levels and Bleeding
- Patients with severe hemophilia A
- N 64 (51 HA, 13 HB)
- Individual PKs defined
- Time FVIII lt1 IU/dL calculated
- Comparison made with joint bleeds over 6 years
- For each additional hour per week FVIII lt1, 1.9
increase in annual hemarthroses
Ahnstrom et al.,Haemophilia 200410689-97
14Clinical Implications
- Modeled data from completed ADVATE clinical
studies - For each additional hour per week with FVIII lt1,
annual bleed rate increased
15Open Questions
- Is chemical modification of very large proteins
feasible, reproducible, and scalable? - Is modified rVWF susceptible to specific
proteolytic degradation by ADAMTS13? - Do modified rFVIII and rVWF retain their
efficacy in vivo? - Does PEGylation impact the immunogenicity of rVWF
and rFVIII?
16Immunogenicity of PEG-FVIII and FVIII in New
Hemophilia Model
17Recombinate Expansion
18Recombinate Expansion
1992 - 1996
19Recombinate Expansion
1992 - 1996
1997 - 2001
20Recombinate Expansion
1992 - 1996
1997 - 2001
2001 - 2007
21Recombinate Expansion
1992 - 1996
1997 - 2001
2001 - 2007
Pending/In Process Registrations
22Acknowledgments
- The Half-life Scientific and Technical Team
- Peter Turecek
- Hans Peter Schwarz
- Birgit Reipert
- Eva Maria Muchitsch
- Bernhard Baumgartner
- Herbert Gritsch
- Katalin Varàdi
- Fritz Scheiflinger
- Wolfgang Mundt
- Artur Mitterer
- Hartmut Ehrlich
- gt150 Team members of Baxter RD currently working
on our hemophilia project